Microwave heat treatment guided by endoscopic ultrasound for advanced pancreatic or liver cancer
Tests a microwave device that heats tumors, in adults with advanced pancreatic or liver cancer.
Plain-language title generated from the registry record
Registry title: CREO - Microwave Ablation Feasibility Study
Key facts
- Where
- Chicago, Gilbert, Houston, Knoxville, Los Angeles, and Morgantown, United StatesSee the 6 sites
Where in United States
- Rush University Medical CenterChicago, United StatesNot yet recruiting
- Banner MD Anderson Cancer Center and Gateway HospitalGilbert, United StatesTaking people
- Memorial Hermann Texas Medical CenterHouston, United StatesNot yet recruiting
- University of Tennessee MedicalKnoxville, United StatesNot yet recruiting
- Cedars SinaiLos Angeles, United StatesNot yet recruiting
- West Virginia University MedicineMorgantown, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Banner Health
- Trial code
- NCT07817147
- Record updated
- 6 November 2026
- Original description
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.Read full original descriptionShow less
Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
Inclusion: Male or female ≥18 years of age; Willing and able to provide written informed consent; Histologically confirmed locally advanced, unresectable or metastatic cancer (Stage III or IV); At least 1 tumor that is indicated for MWA, and the location of target tumor must be accessible via EUS through the gastric wall (eg, pancreas, liver, etc); The tumor(s) must be ≥1 cm in diameter.
Exclusion: Participation in another clinical trial that involves local ablation or any other local therapy that could affect the target organ or lesions treated in this study; Participant is a candidate for upfront resection of pancreatic cancer; Any condition that, in the opinion of the investigator, may increase the risk to the participant's safety or well-being.